Developer docs
API playgroundTry for free, no card

Search company profiles

BioAgilytix Labs

Full company profile

uuid0000rck

Namestring
BioAgilytix Labs
Legal namestring
BioAgilytix Labs, LLC
Websiteurl
bioagilytix.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

BioAgilytix Labs is a global bioanalytical contract research organization (CRO) providing pharmacokinetic (PK), immunogenicity, biomarker, and CMC analytical services to pharmaceutical and biotechnology sponsors. Founded in 2008 and headquartered in Durham, North Carolina, the company operates 355,000+ square feet of GxP-compliant laboratory space across the United States (Durham, Morrisville, Boston, San Diego), Europe (Hamburg), and Australia (Brisbane, Melbourne), with partner labs in Beijing, China. Its scientific teams average 15+ years of bench experience and the Quality function averages 20+ years of regulatory experience, supporting 800+ assays developed and 5,000,000+ tests reported annually for clients that include 22 of the top 25 global pharma and biotech companies.

The company's core technology platform spans liquid chromatography-mass spectrometry (LC/MS), ligand binding and immunoassays (ELISA, MSD-ECL, Luminex, Gyrolab, Biacore), cell-based assays including flow cytometry across multiple instrument platforms, molecular assays (qPCR, ddPCR), and virology with PC2/PC3 and PC4 containment access. CMC analytical services include GMP-compliant cell-based potency assays for monoclonal antibodies, ADCs, AAV and lentiviral gene therapies, and LNP-based therapeutics. In February 2026, the company received an FDA Breakthrough Device Designation for its anti-AAV antibody assay supporting a gene therapy program for Friedreich ataxia cardiomyopathy. The portfolio has expanded through the acquisitions of IPM Biotech (2016), Cambridge Biomedical (2019), MicroConstants (2021), and 360biolabs (2021).

BioAgilytix operates as a privately held LLC incorporated in Delaware and generates revenue through professional services contracts on a project-by-project basis. Pricing is quote-based and varies by study scope, assay type, regulatory framework (GLP/GMP vs non-regulated), sample volume, and turnaround time, with typical engagements structured as multi-year contracts. Go-to-market is enterprise field sales through a scientist-to-scientist consultative model, with senior scientists acting as Bioanalytical Project Managers serving as single points of contact for sponsors. Marketing is driven by scientific thought leadership, peer-reviewed publications, and participation in industry conferences including WRIB, EBF, AAPS PharmSci 360, and CASSS WCBP.

Short descriptiontext

BioAgilytix Labs is a global bioanalytical CRO providing PK, immunogenicity, biomarker, and CMC analytical services in GxP environments to pharmaceutical and biotechnology sponsors, with 1,100+ employees and operations across the US, Europe, and Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioanalytical laboratory services, pharmacokinetic testing, immunogenicity assays, CMC analytical testing, biomarker analysis
Industry5 codes
PRIMARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Bioanalytical Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

BioAgilytix provides bioanalytical testing services to pharmaceutical and biotechnology sponsors on a project-by-project basis. Services span discovery, preclinical, clinical, and CMC phases with fees structured around assay development, validation, and sample analysis. Revenue is project-based with contracts typically scoped for specific studies or programs.

bioagilytix.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Project-based CRO services with pricing determined by study scope
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies by project scope, assay type (PK, immunogenicity, biomarker, CMC), regulatory framework (GLP/GMP vs non-regulated), sample volume, and turnaround time requirements.

bioagilytix.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioAgilytix Labs is a global bioanalytical contract research organization providing pharmacokinetic (PK), immunogenicity, biomarker, pharmacodynamic, DMPK, and CMC analytical services to pharmaceutical and biotechnology sponsors across discovery, preclinical, clinical, and CMC phases. Services are delivered under GLP/GMP/GCP quality systems using LC/MS, immunoassay, cell-based, molecular, and virology platforms across 355,000 sq ft of laboratories in the US, Germany, Australia, and China partner labs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 800+ assays developed annually
+3 more records
Product overview1 text field

BioAgilytix Labs is a global bioanalytical Contract Research Organization (CRO) providing comprehensive laboratory services across drug development phases from discovery through clinical and CMC (Chemistry, Manufacturing, and Controls) testing. The company's core offering is its Bioanalytical Laboratory Services platform encompassing pharmacokinetics (PK), immunogenicity, biomarkers, pharmacodynamics, and drug metabolism (DMPK) testing. This core platform is supported by CMC Analytical Services for quality control and product release testing. The portfolio includes specialized services such as cell-based potency assays, flow cytometry, ligand binding assays, mass spectrometry (LC/MS), molecular assays, virology services, and critical reagent management. The company operates as a unified service provider with acquired brands including 360biolabs (Australia-based virology and immunology expertise) and BioAgilytix San Diego (formerly MicroConstants, providing West Coast LC/MS capabilities). Services span therapeutic modalities including large molecules, small molecules, advanced therapies (ATMPs), vaccines, and support across therapeutic areas such as oncology, immunology, metabolic disease, and neurology.

Product and service14 records
1Bioanalytical Laboratory Services
CategoryBioanalytical Services
Description

Comprehensive bioanalytical testing services including pharmacokinetics (PK), immunogenicity, biomarkers, pharmacodynamics, drug metabolism (DMPK), and diagnostic testing to support drug development across preclinical and clinical phases for pharmaceutical and biotechnology sponsors.

2CMC Analytical Services
CategoryCMC Analytical Services
Description

Chemistry, Manufacturing, and Controls (CMC) analytical development services including bioassay, biophysical, and QC release and stability testing for pharmaceutical product quality assurance across biologics, ADCs, gene therapies, and vaccines.

3Immunogenicity Testing Services
CategoryBioanalytical Services
Description

Anti-drug antibody (ADA) and neutralizing antibody (NAb) assay services assessing the immunogenicity of biological drugs and their impact on pharmacokinetics and efficacy for biologics developers.

4Biomarker Testing Services
CategoryBioanalytical Services
Description

Biomarker analysis services supporting clinical trial efficacy and safety, with over 500 biomarkers validated in singleplex and multiplex formats for pharma and biotech sponsors.

5Pharmacokinetics (PK) Assay Services
CategoryBioanalytical Services
Description

PK assay development and sample analysis evaluating absorption, distribution, metabolism, and excretion characteristics of drug products for pharmaceutical and biotechnology sponsors.

6Virology Services
CategorySpecialty Bioanalytical Services
Description

Virological expertise including classical virology (culture and PRNT), molecular PCR, and support for vaccine and antiviral discovery and development, executed in physical containment 2, 3, and 4 laboratories for vaccine and antiviral developers.

7Mass Spectrometry (LC/MS) Services
CategorySpecialty Bioanalytical Services
Description

Liquid chromatography-mass spectrometry services for bioanalytical testing supporting both regulated and non-regulated bioanalysis across complex biological and chemical entities for pharmaceutical and biotechnology sponsors.

8Cell-Based Potency Assay Services
CategoryCMC Analytical Services
Description

Regulatory-recommended cell-based assays for product release and stability testing that evaluate efficacy, quality, and consistency of drug lots, supporting monoclonal antibodies, ADCs, gene therapies, and vaccines.

9Drug-Drug Interaction Studies
CategorySpecialty Bioanalytical Services
Description

In vitro evaluation services for CYP450 induction, CYP/UGT inhibition, reaction phenotyping, and transporter substrate/inhibition studies per FDA guidance for small molecule drug developers.

10Dose Formulation Analysis Services
CategoryPreclinical Bioanalytical Services
Description

Preclinical dose formulation analysis for GLP and non-GLP studies including method validation, homogeneity, stability, and Certificate of Analysis generation for pharmaceutical and biotechnology sponsors.

11Toxicology Support Services
CategoryPreclinical Bioanalytical Services
Description

GLP and non-GLP toxicology study support including PK/toxicokinetics, ADA/NAb, biomarkers, and multiplex cytokine panels for safety assessment in drug development programs.

12Anti-AAV Antibody Assay (FDA Breakthrough Device Designation)
CategorySpecialty Bioanalytical Services
Description

Proprietary anti-AAV antibody assay with FDA Breakthrough Device Designation enabling precise patient selection and monitoring for AAV-based gene therapy programs, including support for Lexeo Therapeutics' Friedreich ataxia cardiomyopathy program.

13360biolabs (a BioAgilytix Company)
CategoryAcquired Brand / Regional Service
Description

Australian contract research organization brand providing expertise in virology, immunology, and bioanalytical services with facilities in Brisbane and Melbourne, now operating as a BioAgilytix Company.

14BioAgilytix San Diego (formerly MicroConstants)
CategoryAcquired Brand / Regional Service
Description

San Diego-based bioanalytical testing laboratory brand specializing in LC/MS, HPLC, and bioanalytical techniques for West Coast pharmaceutical support, now operating as BioAgilytix San Diego.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-14
Description

BioAgilytix completed acquisition of Australia's 360biolabs, a contract research organization with expertise in virology, immunology, and bioanalytical services. The acquisition expanded BioAgilytix's global presence and clinical trial support capabilities in Australia. Operates as BioAgilytix Brisbane and Melbourne locations.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Labcorp operates one of the largest global central and bioanalytical lab networks as part of its clinical development services. Competes with BioAgilytix on bioanalytical scale, GxP compliance, and global clinical trial support for pharma/biotech sponsors.

TypeDirect peer
Description

Frontage is a contract research organization providing bioanalytical, CMC, and preclinical lab services to pharma and biotech. Directly comparable to BioAgilytix in its bioanalytical/LBA/LC-MS core, biologics CMC focus, and global expansion playbook (including acquisitions).

TypeBroad incumbent
Description

Charles River is a large, publicly traded CRO with a significant bioanalytical and safety assessment footprint serving global pharma and biotech. It competes with BioAgilytix for bioanalytical work as part of a broader CRO portfolio.

TypeBroad incumbent
Description

IQVIA is a diversified clinical development and lab services provider with bioanalytical and central lab capabilities. Overlaps with BioAgilytix on biomarker, immunogenicity, and PK/PD testing as part of integrated clinical offerings.

TypeDirect peer
Description

Celerion is a specialty CRO focused on early-stage clinical pharmacology, bioanalytical services, and PK/PD analysis. Closely aligned with BioAgilytix's early-phase, large-molecule bioanalytical work and sponsor base.

TypeBroad incumbent
Description

Eurofins operates a global network of pharma testing and bioanalytical laboratories serving drug development and clinical trials. Competes with BioAgilytix on LC/MS, immunoassay, and biomarker services as part of a broad testing portfolio.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-sized CRO with bioanalytical and clinical pharmacology services for biotech and pharma. Comparable to BioAgilytix in mid-market CRO positioning, bioanalytical depth, and therapeutic-area focus.

TypeBroad incumbent
Description

PPD, now part of Thermo Fisher, is a global CRO with central lab and bioanalytical capabilities supporting clinical development. Competes with BioAgilytix for central lab and biomarker work bundled with clinical operations.

TypeRegional player
Description

WuXi AppTec and WuXi Biologics provide bioanalytical and biologics CMC services primarily from China-based facilities. Comparable capabilities and modality coverage to BioAgilytix, but primarily serves global sponsors via Asia-based operations.

TypeEmerging player
Description

Altasciences is a mid-market CRO providing bioanalytical, clinical, and preclinical services with growing biologics capability. Comparable to BioAgilytix in early-phase bioanalytical focus and biotech sponsor orientation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioAgilytix Labs

Bioanalytical Contract Research Servicesbioagilytix.com

BioAgilytix Labs is a global bioanalytical CRO providing PK, immunogenicity, biomarker, and CMC analytical services in GxP environments to pharmaceutical and biotechnology sponsors, with 1,100+ employees and operations across the US, Europe, and Australia.

What BioAgilytix Labs does

BioAgilytix Labs is a global bioanalytical contract research organization (CRO) providing pharmacokinetic (PK), immunogenicity, biomarker, and CMC analytical services to pharmaceutical and biotechnology sponsors. Founded in 2008 and headquartered in Durham, North Carolina, the company operates 355,000+ square feet of GxP-compliant laboratory space across the United States (Durham, Morrisville, Boston, San Diego), Europe (Hamburg), and Australia (Brisbane, Melbourne), with partner labs in Beijing, China. Its scientific teams average 15+ years of bench experience and the Quality function averages 20+ years of regulatory experience, supporting 800+ assays developed and 5,000,000+ tests reported annually for clients that include 22 of the top 25 global pharma and biotech companies.

The company's core technology platform spans liquid chromatography-mass spectrometry (LC/MS), ligand binding and immunoassays (ELISA, MSD-ECL, Luminex, Gyrolab, Biacore), cell-based assays including flow cytometry across multiple instrument platforms, molecular assays (qPCR, ddPCR), and virology with PC2/PC3 and PC4 containment access. CMC analytical services include GMP-compliant cell-based potency assays for monoclonal antibodies, ADCs, AAV and lentiviral gene therapies, and LNP-based therapeutics. In February 2026, the company received an FDA Breakthrough Device Designation for its anti-AAV antibody assay supporting a gene therapy program for Friedreich ataxia cardiomyopathy. The portfolio has expanded through the acquisitions of IPM Biotech (2016), Cambridge Biomedical (2019), MicroConstants (2021), and 360biolabs (2021).

BioAgilytix operates as a privately held LLC incorporated in Delaware and generates revenue through professional services contracts on a project-by-project basis. Pricing is quote-based and varies by study scope, assay type, regulatory framework (GLP/GMP vs non-regulated), sample volume, and turnaround time, with typical engagements structured as multi-year contracts. Go-to-market is enterprise field sales through a scientist-to-scientist consultative model, with senior scientists acting as Bioanalytical Project Managers serving as single points of contact for sponsors. Marketing is driven by scientific thought leadership, peer-reviewed publications, and participation in industry conferences including WRIB, EBF, AAPS PharmSci 360, and CASSS WCBP.

BioAgilytix Labs firmographics

Firmographics
Name
BioAgilytix Labs
Legal name
BioAgilytix Labs, LLC
Website
https://bioagilytix.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
501–1,000 employees
Short description
BioAgilytix Labs is a global bioanalytical CRO providing PK, immunogenicity, biomarker, and CMC analytical services in GxP environments to pharmaceutical and biotechnology sponsors, with 1,100+ employees and operations across the US, Europe, and Australia.
Ownership category
akta.pro rank

BioAgilytix Labs industry classification

Industry
Product category
Bioanalytical Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories

Keywords

  • Bioanalytical laboratory services
  • Pharmacokinetic testing
  • Immunogenicity assays
  • CMC analytical testing
  • Biomarker analysis

Where BioAgilytix Labs is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices8 records

Markets served

BioAgilytix Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Contract Research Services: BioAgilytix provides bioanalytical testing services to pharmaceutical and biotechnology sponsors on a project-by-project basis. Services span discovery, preclinical, clinical, and CMC phases with fees structured around assay development, validation, and sample analysis. Revenue is project-based with contracts typically scoped for specific studies or programs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based CRO services with pricing determined by study scope

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

BioAgilytix Labs product offering

Product offering

Core offering

BioAgilytix Labs is a global bioanalytical contract research organization providing pharmacokinetic (PK), immunogenicity, biomarker, pharmacodynamic, DMPK, and CMC analytical services to pharmaceutical and biotechnology sponsors across discovery, preclinical, clinical, and CMC phases. Services are delivered under GLP/GMP/GCP quality systems using LC/MS, immunoassay, cell-based, molecular, and virology platforms across 355,000 sq ft of laboratories in the US, Germany, Australia, and China partner labs.

Product overview

BioAgilytix Labs is a global bioanalytical Contract Research Organization (CRO) providing comprehensive laboratory services across drug development phases from discovery through clinical and CMC (Chemistry, Manufacturing, and Controls) testing. The company's core offering is its Bioanalytical Laboratory Services platform encompassing pharmacokinetics (PK), immunogenicity, biomarkers, pharmacodynamics, and drug metabolism (DMPK) testing. This core platform is supported by CMC Analytical Services for quality control and product release testing. The portfolio includes specialized services such as cell-based potency assays, flow cytometry, ligand binding assays, mass spectrometry (LC/MS), molecular assays, virology services, and critical reagent management. The company operates as a unified service provider with acquired brands including 360biolabs (Australia-based virology and immunology expertise) and BioAgilytix San Diego (formerly MicroConstants, providing West Coast LC/MS capabilities). Services span therapeutic modalities including large molecules, small molecules, advanced therapies (ATMPs), vaccines, and support across therapeutic areas such as oncology, immunology, metabolic disease, and neurology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bioanalytical Laboratory Services Comprehensive bioanalytical testing services including pharmacokinetics (PK), immunogenicity, biomarkers, pharmacodynamics, drug metabolism (DMPK), and diagnostic testing to support drug development across preclinical and clinical phases for pharmaceutical and biotechnology sponsors.
  • CMC Analytical Services Chemistry, Manufacturing, and Controls (CMC) analytical development services including bioassay, biophysical, and QC release and stability testing for pharmaceutical product quality assurance across biologics, ADCs, gene therapies, and vaccines.
  • Immunogenicity Testing Services Anti-drug antibody (ADA) and neutralizing antibody (NAb) assay services assessing the immunogenicity of biological drugs and their impact on pharmacokinetics and efficacy for biologics developers.
  • Biomarker Testing Services Biomarker analysis services supporting clinical trial efficacy and safety, with over 500 biomarkers validated in singleplex and multiplex formats for pharma and biotech sponsors.
  • Pharmacokinetics (PK) Assay Services PK assay development and sample analysis evaluating absorption, distribution, metabolism, and excretion characteristics of drug products for pharmaceutical and biotechnology sponsors.
  • Virology Services Virological expertise including classical virology (culture and PRNT), molecular PCR, and support for vaccine and antiviral discovery and development, executed in physical containment 2, 3, and 4 laboratories for vaccine and antiviral developers.
  • Mass Spectrometry (LC/MS) Services Liquid chromatography-mass spectrometry services for bioanalytical testing supporting both regulated and non-regulated bioanalysis across complex biological and chemical entities for pharmaceutical and biotechnology sponsors.
  • Cell-Based Potency Assay Services Regulatory-recommended cell-based assays for product release and stability testing that evaluate efficacy, quality, and consistency of drug lots, supporting monoclonal antibodies, ADCs, gene therapies, and vaccines.
  • Drug-Drug Interaction Studies In vitro evaluation services for CYP450 induction, CYP/UGT inhibition, reaction phenotyping, and transporter substrate/inhibition studies per FDA guidance for small molecule drug developers.
  • Dose Formulation Analysis Services Preclinical dose formulation analysis for GLP and non-GLP studies including method validation, homogeneity, stability, and Certificate of Analysis generation for pharmaceutical and biotechnology sponsors.
  • Toxicology Support Services GLP and non-GLP toxicology study support including PK/toxicokinetics, ADA/NAb, biomarkers, and multiplex cytokine panels for safety assessment in drug development programs.
  • Anti-AAV Antibody Assay (FDA Breakthrough Device Designation) Proprietary anti-AAV antibody assay with FDA Breakthrough Device Designation enabling precise patient selection and monitoring for AAV-based gene therapy programs, including support for Lexeo Therapeutics' Friedreich ataxia cardiomyopathy program.
  • 360biolabs (a BioAgilytix Company) Australian contract research organization brand providing expertise in virology, immunology, and bioanalytical services with facilities in Brisbane and Melbourne, now operating as a BioAgilytix Company.
  • BioAgilytix San Diego (formerly MicroConstants) San Diego-based bioanalytical testing laboratory brand specializing in LC/MS, HPLC, and bioanalytical techniques for West Coast pharmaceutical support, now operating as BioAgilytix San Diego.

Quantifiable outcome

  • 800+ assays developed annually
  • +3 more outcomes

Companies that use BioAgilytix Labs

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

BioAgilytix Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

BioAgilytix Labs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • 360biolabscoreStrategic or Co-development Partner · 14 October 2021BioAgilytix completed acquisition of Australia's 360biolabs, a contract research organization with expertise in virology, immunology, and bioanalytical services. The acquisition expanded BioAgilytix's global presence and clinical trial support capabilities in Australia. Operates as BioAgilytix Brisbane and Melbourne locations.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

BioAgilytix Labs competitors and assessment

Company assessment

Broad incumbents

  • Labcorp Drug Development (formerly Covance): Labcorp operates one of the largest global central and bioanalytical lab networks as part of its clinical development services. Competes with BioAgilytix on bioanalytical scale, GxP compliance, and global clinical trial support for pharma/biotech sponsors.
  • Charles River Laboratories: Charles River is a large, publicly traded CRO with a significant bioanalytical and safety assessment footprint serving global pharma and biotech. It competes with BioAgilytix for bioanalytical work as part of a broader CRO portfolio.
  • IQVIA: IQVIA is a diversified clinical development and lab services provider with bioanalytical and central lab capabilities. Overlaps with BioAgilytix on biomarker, immunogenicity, and PK/PD testing as part of integrated clinical offerings.
  • Eurofins Scientific: Eurofins operates a global network of pharma testing and bioanalytical laboratories serving drug development and clinical trials. Competes with BioAgilytix on LC/MS, immunoassay, and biomarker services as part of a broad testing portfolio.
  • PPD (Thermo Fisher Scientific): PPD, now part of Thermo Fisher, is a global CRO with central lab and bioanalytical capabilities supporting clinical development. Competes with BioAgilytix for central lab and biomarker work bundled with clinical operations.

Direct peers

  • Frontage Laboratories: Frontage is a contract research organization providing bioanalytical, CMC, and preclinical lab services to pharma and biotech. Directly comparable to BioAgilytix in its bioanalytical/LBA/LC-MS core, biologics CMC focus, and global expansion playbook (including acquisitions).
  • Celerion: Celerion is a specialty CRO focused on early-stage clinical pharmacology, bioanalytical services, and PK/PD analysis. Closely aligned with BioAgilytix's early-phase, large-molecule bioanalytical work and sponsor base.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with bioanalytical and clinical pharmacology services for biotech and pharma. Comparable to BioAgilytix in mid-market CRO positioning, bioanalytical depth, and therapeutic-area focus.

Regional players

  • WuXi AppTec / WuXi Biologics: WuXi AppTec and WuXi Biologics provide bioanalytical and biologics CMC services primarily from China-based facilities. Comparable capabilities and modality coverage to BioAgilytix, but primarily serves global sponsors via Asia-based operations.

Emerging players

  • Altasciences: Altasciences is a mid-market CRO providing bioanalytical, clinical, and preclinical services with growing biologics capability. Comparable to BioAgilytix in early-phase bioanalytical focus and biotech sponsor orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

BioAgilytix Labs social profiles

Digital presence

BioAgilytix Labs compliance and trust

Trust signal

Compliance4 records

BioAgilytix Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioAgilytix Labs leadership team

Management profile

Number of profiles

Profiles6 records

BioAgilytix Labs subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

BioAgilytix Labs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioAgilytix Labs M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioAgilytix Labs

What does BioAgilytix Labs do?

BioAgilytix Labs is a global bioanalytical contract research organization providing pharmacokinetic (PK), immunogenicity, biomarker, pharmacodynamic, DMPK, and CMC analytical services to pharmaceutical and biotechnology sponsors across discovery, preclinical, clinical, and CMC phases. Services are delivered under GLP/GMP/GCP quality systems using LC/MS, immunoassay, cell-based, molecular, and virology platforms across 355,000 sq ft of laboratories in the US, Germany, Australia, and China partner labs.

Is BioAgilytix Labs a public or private company?

BioAgilytix Labs is a private company. It is classified as private equity controlled and is currently operating.

When was BioAgilytix Labs founded?

BioAgilytix Labs was founded in 2008. It employs 501 to 1,000 people.

Where is BioAgilytix Labs based?

BioAgilytix Labs is headquartered in Durham, United States, in the North America region.

How does BioAgilytix Labs make money?

One revenue line is on record: contract Research Services.

Who are BioAgilytix Labs's main competitors?

Broad incumbents on record are Labcorp Drug Development (formerly Covance), Charles River Laboratories, IQVIA, Eurofins Scientific and PPD (Thermo Fisher Scientific). Direct peers are Frontage Laboratories, Celerion and Worldwide Clinical Trials. WuXi AppTec / WuXi Biologics is listed as a regional player. Altasciences is listed as an emerging player.

Does BioAgilytix Labs have an API?

No public API is recorded for BioAgilytix Labs.

What industry is BioAgilytix Labs in?

BioAgilytix Labs's product category is Bioanalytical Contract Research Services. Its primary akta.pro industry code is HLAGAEAG, Bioanalytical & PK/PD Sample Analysis (Trial Support), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsFast 50 winners reveal strategies for success (podcast)A podcast episode features executives from Aspida, BioAgilytix, and Audio Advice, winners of the 2026 Fast 50 Awards, discussing their growth strategies. They emphasize creating customer value, building the right culture, and avoiding legacy competitor behaviors.GenengnewsFormulation Development RoundupFour formulation development companies—Abzena, BioAgilytix, Curia Global, and Quotient Sciences—outlined their approaches to developing new drug formulations. They emphasized early risk assessment, stability studies, and demonstrating robustness across variability rather than just initial screen performance. Long-term stability data is cited as the gold standard for confirming a robust formulation.EIN PresswireBioAgilytix Expands Global Bioanalytical Capabilities Through New 360biolabs Sydney LaboratoryBioAgilytix opened a new purpose-designed BSL-2 laboratory for its 360biolabs subsidiary in Sydney, Australia, to support early-phase clinical development. The facility, located in Macquarie Park, is NATA-accredited to ISO/IEC 17025 and strengthens BioAgilytix's global bioanalytical capabilities.EIN PresswireBioAgilytix Expands Global Bioanalytical Capabilities Through New 360biolabs Sydney LaboratoryBioAgilytix opened a new purpose-designed laboratory for its 360biolabs subsidiary in Sydney, Australia, within the Macquarie Park Innovation District. The BSL-2 facility supports PBMC isolation, flow cytometry, and cryostorage, and is accredited to ISO/IEC 17025. The expansion strengthens BioAgilytix's global bioanalytical capabilities for early-phase clinical development.EIN PresswireBioAgilytix Demonstrates Expanded GMP Analytical Capacity One Year After Strategic Investment in MorrisvilleBioAgilytix highlighted its expanded GMP analytical capacity one year after investing in Morrisville and Hamburg facilities. The expansion added dedicated GMP QC infrastructure and bioassay capability, supporting clients across modalities. The company continues investing in technology and capacity to meet evolving regulatory expectations.EIN PresswireBioAgilytix Labs, Inc Receives FDA Breakthrough Device Designation for Anti-AAV Antibody AssayBioAgilytix Labs has received FDA Breakthrough Device Designation for its anti-AAV antibody assay developed to support Lexeo Therapeutics' gene therapy program for Friedreich ataxia cardiomyopathy. The designation, granted to one of a limited number of CROs to receive BDD for a diagnostic assay supporting an investigational device exemption, provides expedited development, enhanced FDA interaction, and priority review toward market access. This recognition underscores the assay's potential to address an unmet clinical need by enabling precise patient selection and monitoring for gene therapy programs targeting the rare disorder affecting approximately 15,000 individuals worldwide.BioAgilytixCMC Analytical DevelopmentCMC Analytical Development involves critical processes in drug development ensuring safety, efficacy, and quality of pharmaceutical products through various analytical methods. BioAgilytix is highlighted as a leading CRO partner providing CMC analytical services to ensure compliance and risk mitigation throughout the drug development stages. The article emphasizes the importance of CMC strategies and analytical services in meeting regulatory requirements and supporting successful therapeutic programs.American City Business JournalsFormer BioAgilytix CEO Jim Datin joins GHO CapitalJim Datin, former CEO of BioAgilytix, has joined GHO Capital after leading the CRO to significant growth before its private equity acquisition. He now seeks to find the next big investment in the Triangle.Financial TimesFinal Results – Company AnnouncementCaledonia Investments reported final results for the year ended 31 March 2022, with net assets of £2.78bn, a 27.9% NAV total return and a full-year dividend of 64.8p per share, up 3.0%. The board recommended a special dividend of 175p, worth £95m, following the £242m sale of Deep Sea Electronics and the US$183m BioAgilytix deal. CEO Will Wyatt retires in July, succeeded by Mathew Masters.PR NewswireBioAgilytix bemachtigt omvangrijke nieuwe investeringen van mondiaal investeerder Cinven voor verdere langetermijngroeiCinven has acquired a majority stake in BioAgilytix, with Cobepa retaining a significant minority interest. This investment provides the contract research organization with additional capital to expand its global footprint and enhance operational capabilities to meet growing demand for bioanalytical services. The transaction is expected to close following standard conditions and regulatory approvals.